Pablo Corral on Lipid-Lowering Therapy and Cognition: Evidence vs Myth
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Lipid-Lowering Therapy and Cognition: Evidence vs Myth
1. Elevated LDL-C remains the leading modifiable risk factor for cardiovascular disease and a major contributor to global mortality.
2. Concerns about cognitive adverse effects of lipid-lowering therapies (LLTs), particularly statins, are largely driven by early case reports rather than robust clinical evidence.
3. Observational studies and randomized trials consistently show no significant association between statin use and cognitive decline, with some data suggesting potential protective effects against dementia.
4. Major randomized trials (HPS, PROSPER, HOPE-3) found no difference in cognitive outcomes between statin-treated and placebo groups.
5. PCSK9 inhibitors (evolocumab, alirocumab) demonstrate neurocognitive safety, even with very low LDL-C levels and long-term exposure.
6. Ezetimibe and bempedoic acid show neutral neurocognitive profiles, with emerging signals of possible neuroprotective effects.
Current data support a clear conclusion:
- Lowering LDL-C improves cardiovascular outcomes without meaningful cognitive harm.
- The real knowledge gap is not safety, but understanding whether lipid-lowering therapies might also confer long-term neuroprotection.
Take-home message:
Fear of cognitive decline should not justify therapeutic inertia.
The price of untreated LDL-C is cardiovascular disease—not cognitive impairment.”
Read the full article here.
Article: Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
Authors: Raiza Rossi, Armin Nouri, Zafer Akman, Shefa Arya Nezhad, Abdulla A. Damluji, Michael G. Nanna
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 26, 2026, 08:52Teresa Gisinger Sex Hormones and Cardiovascular Risk in Type 2 DM
-
Jan 26, 2026, 07:01Pedro Perez on Deep Vein Thrombosis in 2026: Getting the First Decisions Right
-
Jan 26, 2026, 05:40Vicki Kopplin Offers Immediate Funding for People With Bleeding Disorders
-
Jan 26, 2026, 05:27Jill Storry on Alloimmune Hemolytic Disease of the Fetus And Newborn
-
Jan 26, 2026, 05:09Wathsala Manindrani Gives a A Practical Perspective on Red Cell Exchange Transfusion
-
Jan 26, 2026, 04:59Abdul Mannan: BDUC – 4 Letters That Make Many Haematologists Uncomfortable
-
Jan 26, 2026, 04:51Manoj Kumar Singh: Power In Me Foundation Celebrates 2026 as Year Of Rare
-
Jan 26, 2026, 04:40Heghine Khachatryan: Did You Know VWD Comprises 3 Main Types?
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial